Year: 2021

news_6

RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting

Data show a consistent safety profile and potential BCVA benefit in wAMD patients with suboptimal response to prior anti-VEGF therapy...